Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma
Acta Pharmaceutica Sinica B · 2026-02 · 16 (2) · 802-819
DOI: 10.1016/j.apsb.2025.12.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-02. Verfasst von Yue Ma und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Program of Shanghai Academic Research Leader, National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
The susceptibility to ferroptosis partially determines the efficacy of tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC), exposing a mechanistic vulnerability that can be therapeutically exploited. The development of deuterated compounds is a promising strategy for the improvement of anti-tumor efficacy. Here, we identified HCC with higher level of ferroptosis-resistance exhibited insensitive to TKIs, which could be reversed by deuterated TKIs. Aldehyde oxidase 1 (AOX1) was screened as a critical gene mediating the responsiveness to deuterated TKIs-induced ferroptosis in HCC. The presence of a pyridyl tri-deuterated methanamide contributed to the upregulation of AOX1 in a structure-dependent manner, thereby promoting ferroptosis. Mechanistically, AOX1 inhibited sirtuin 6-mediated deacetylation of H3K9 and H3K56, leading to transcriptional activation of acyl-CoA synthetase long chain family member 5, which resulted in poly-unsaturated fatty acids hyperaccumulation-induced ferroptosis. Additionally, HCC with lower AOX1 expression conferred better efficacy to deuterated TKIs. In patient cohorts with HCC, those with lower AOX1 expression exhibited a more pronounced therapeutic response to deuterated sorafenib. Overall, the present study elucidates the mechanism by which deuterated TKIs reverse TKI resistance by promoting ferroptosis and suggests that AOX1 could serve as a biomarker to guide clinical decision-making for deuterated TKI treatment in HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China.
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Förderung
- Program of Shanghai Academic Research Leader
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
Zitieren
APA
Ma, Y., Yi, C., Cai, N., Tao, B., Geng, Y., Shao, W., Sun, R., Chen, Z., Li, Y., Zhang, B., Wang, X., Lin, J., Zhu, W., Lu, L., Zhang, W., & Chen, J. (2026). Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma. Acta Pharmaceutica Sinica B, 16(2), 802-819. https://doi.org/10.1016/j.apsb.2025.12.007
Vancouver
Ma Y, Yi C, Cai N, Tao B, Geng Y, Shao W, et al. Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma. Acta Pharmaceutica Sinica B. 2026;16(2):802-819. doi:10.1016/j.apsb.2025.12.007
BibTeX
@article{Ma2026,
author = {Ma, Yue and Yi, Chenhe and Cai, Ning and Tao, Baorui and Geng, Yan and Shao, Weiqing and Sun, Rongquan and Chen, Zhenmei and Li, Yitong and Zhang, Bo and Wang, Xiangyu and Lin, Jing and Zhu, Wenwei and Lu, Lu and Zhang, Wanguang and Chen, Jinhong},
title = {Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {2},
pages = {802--819},
doi = {10.1016/j.apsb.2025.12.007}
}
EUVIMED